Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio.
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1559-61. doi: 10.1016/j.cgh.2013.10.001. Epub 2013 Oct 6.
Achieving the best possible outcomes requires the reliable implementation of best practices for every patient. Specifically, optimizing outcomes requires a spectrum of research spanning basic science, drug development, clinical efficacy and effectiveness, health services, quality improvement, and implementation research. However, our rapid increase in understanding the mechanisms of health and disease and their treatment has far outpaced our ability to reliably provide that care, resulting in poor reliability and enormous variation in care. T3 translational research studies attempt to answer questions surrounding reliable implementation of interventions, decreasing variations in care, and spreading effective therapies. To answer these questions, T3 research may use traditional research methodology such as randomized controlled trials (RCTs); however, various other approaches such as quasiexperimental designs (eg, time-series analysis) are often used. Although uncommon, T3 research has shown promise in not only improving process measures such as correct dosing of medications, but also outcome measures such as improved remission rates in patients with IBD. A more complete integration of T3 translational research into the more traditional research continuum is necessary if we are to achieve the best possible outcomes for our patients.
为了实现最佳结果，需要为每位患者可靠地实施最佳实践。具体来说，优化结果需要一系列研究，涵盖基础科学、药物开发、临床疗效和效果、医疗服务、质量改进和实施研究。然而，我们对健康和疾病机制及其治疗的理解迅速增加，已经远远超过了我们可靠提供护理的能力，导致护理的可靠性差且差异巨大。T3 转化研究试图回答围绕干预措施可靠实施、减少护理差异和传播有效治疗方法的问题。为了回答这些问题，T3 研究可能使用传统的研究方法，如随机对照试验（RCT）；然而，通常还使用其他各种方法，如准实验设计（例如，时间序列分析）。尽管不常见，但 T3 研究不仅在改善药物正确剂量等过程指标方面显示出前景，而且在改善 IBD 患者缓解率等结果指标方面也显示出前景。如果我们要为患者实现最佳结果，就需要将 T3 转化研究更完整地纳入更传统的研究连续体中。
